Animal data and anecdotal human experience suggest that vascular damage induced by the infusion of dextrose/amino acid solutions may be ameliorated by the concomitant administration of fat emulsion. We prospectively evaluated the effect of the continuous infusion of peripheral nutrition solutions with and without fat emulsion on the incidence of, probability of, and time to infiltration of peripheral venous lines in infants (median age: 1.0 month; range 1 day-11.9 months). Ninety-seven peripheral venous lines were studied in 53 infants who received 10% dextrose (n = 34), 10% dextrose/2% amino acids (n = 30), or 10% dextrose/2% amino acids/fat emulsion (n = 33). Solutions were administered by positive pressure infusion devices through Teflon catheters with similar gauge. Dextrose, amino acid, electrolyte, and mineral content was standardized for the dextrose/amino acid and dextrose/amino acid/fat emulsion groups. The three groups were similar with respect to age, race, gender, weight, administration of intravenous medications, and catheter site (p greater than 0.05). Patients receiving dextrose/amino acid or dextrose/amino acid/fat emulsion had greater rates of solution administration than those receiving dextrose alone (p less than 0.002). Infiltration occurred in 71% of dextrose, 66% of dextrose/amino acid, and 67% of dextrose/amino acid/fat emulsion solutions (p greater than 0.05). The probability of infiltration was greater for infants receiving dextrose/amino acid than for those receiving either dextrose or dextrose/amino acid/fat emulsion (p = 0.01). The mean +/- SEM length of time the intravenous sites were viable was significantly shorter for the dextrose/amino acid solutions (26.3 +/- 3.3 hr) compared to the dextrose (54.9 +/- 7.8 hr) and dextrose/amino acid/fat emulsion (43.6 +/- 4.2 hr) groups. No site complications were associated with the infiltration of any solution. We conclude that the incidence of infiltration among the three solution groups studied is not different. However, the time to infiltration is prolonged and the probability of infiltration is decreased following the infusion of either dextrose alone or dextrose/amino acid/fat emulsion solutions when compared to the administration of dextrose/amino acid solutions without concomitant fat emulsion infusion.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/0148607189013006628 | DOI Listing |
Clin Nutr ESPEN
August 2022
Research and Development Center, Otsuka Pharmaceutical Factory Inc., Tokyo 101-0052, Japan. Electronic address:
Background & Aims: We developed the world's first all-in-one type peripheral parenteral nutrition product containing dextrose, amino acids, fat emulsion, electrolytes and vitamins, according to the FDA 2000 recommendation. This phase I trial examined the safety and changes in nutritional parameters in healthy participants.
Methods: A single-center, randomized, open-label, active-controlled trial was performed in single ascending dose (SAD: Step 1-3) and multiple dose (Step 4) studies.
J Pharm Bioallied Sci
December 2020
Department of Pharmacy, University of Islam Indonesia, Yogyakarta, Indonesia.
Introduction: All-in-one parenteral nutrition (AIO-PN) is essential for patients with limited venous access, e.g. premature infants.
View Article and Find Full Text PDFInt J Pharm Compd
October 2020
International Journal of Pharmaceutical Compounding.
In the formulation of parenteral dosage forms, pH is a critical factor and can be a complicated factor in compounding intravenous admixtures since the additives and the vehicle may have different pH values. This is especially important, as a significant number of parenteral medications require compounding involving dissolution of lyophilized powders; dilution of drug doses for infusion; mixing of dextrose, amino acids, vitamins, and electrolytes for parenteral nutrition; etc. Compounding intravenous admixtures is common practice, but each admixture may present a different set of problems to consider, especially as it relates to pH.
View Article and Find Full Text PDFInt J Pharm Compd
July 2020
International Journal of Pharmaceutical Compounding.
The effect of pH on solubility and stability is a critical factor in the formulation of parenteral dosage forms and becomes more complicated in intravenous admixtures since the additives and the vehicle may have different pH values. This is especially important as a significant number of parenteral medications require some compounding involving dissolution of lyophilized powders, dilution of drug doses for infusion, mixing of dextrose, amino acids, vitamins, and electrolytes for parenteral nutrition, etc. A change in the acid-base environment of a drug involves both the solubility and stability characteristics and can be critically related to pH as follows: (1) as a solution goes away from the pH of maximum solubility, the drug can precipitate out of solution, and (2) as the solution goes away from the pH of maximum stability, the drug can degrade more rapidly and have a short beyond-use date.
View Article and Find Full Text PDFNutrients
September 2019
Department of Nutrition, Université de Montréal, 2405 Chemin de la Côte-Sainte-Catherine, Montréal, QC H3T 1A8, Canada.
Peroxides contaminating parenteral nutrition (PN) limit the use of methionine as a precursor of cysteine. Thus, PN causes a cysteine deficiency, characterized by low levels of glutathione, the main molecule used in peroxide detoxification, and limited growth in individuals receiving long-term PN compared to the average population. We hypothesize that glutathione supplementation in PN can be used as a pro-cysteine that improves glutathione levels and protein synthesis and reduces oxidative stress caused by PN.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!